Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - Should You Buy?

Key Points

• Takeda Pharmaceutical's shares reached a new 52-week high of $15.56 during trading, with the latest price recorded at $15.50.
• The company reported earnings of $0.52 per share, exceeding analyst expectations of $0.47, but fell short on revenue with $7.45 billion against a $7.96 billion estimate.
• Institutional investors such as JPMorgan Chase and Russell Investments have significantly increased their stakes in Takeda Pharmaceutical, indicating growing confidence in the stock.

Shares of Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $15.56 and last traded at $15.50, with a volume of 711159 shares. The stock had previously closed at $15.20.

Takeda Pharmaceutical Stock Performance

The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The business has a 50-day moving average price of $14.79 and a 200-day moving average price of $14.64. The firm has a market capitalization of $49.34 billion, a price-to-earnings ratio of 51.65 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in TAK. JPMorgan Chase & Co. boosted its holdings in Takeda Pharmaceutical by 94.5% in the fourth quarter. JPMorgan Chase & Co. now owns 83,826 shares of the company's stock valued at $1,110,000 after purchasing an additional 40,721 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Takeda Pharmaceutical by 48.6% in the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock valued at $600,000 after purchasing an additional 14,831 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth about $1,447,000. Townsquare Capital LLC purchased a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth about $151,000. Finally, Mariner LLC boosted its stake in shares of Takeda Pharmaceutical by 14.0% during the 4th quarter. Mariner LLC now owns 142,504 shares of the company's stock worth $1,887,000 after acquiring an additional 17,525 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.